SCHEMBL24603653

SCHEMBL24603653

COC(=O)c1cnc2c3ccc4c5c(cnc(c6ccc(C(=O)N(CCc7ccccc7)Cc7ccc(OC)cc7)c1c62)c53)C(=O)N(C)C4=O

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LPAR1 Q92633 6/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ LPAR5 Q9H1C0 2/20 0.43
▸ TSHR P16473 2/20 0.40
▸ PKM P14618 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ TDP1 Q9NUW8 2/20 0.39
▸ TP53 P04637 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ LMNA P02545 1/20 0.38
▸ KLK1 P06870 1/20 0.37
▸ ADORA1 P30542 1/20 0.37
▸ HDAC1 Q13547 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24603654 0.94 LPAR1 (0.42) LPAR1MEN1KMT2ALPAR5TSHR
SCHEMBL24603649 0.91 LPAR1 (0.39) LPAR1MEN1KMT2ALPAR5TSHR
SCHEMBL24603670 0.86 ALDH1A1 (0.40) MEN1KMT2ASMN1; SMN2TDP1TP53
SCHEMBL24603652 0.81 LPAR1 (0.42) LPAR1MEN1KMT2ALPAR5TSHR
SCHEMBL24603671 0.75 ALDH1A1 (0.46) MEN1KMT2ATSHRPKMSMN1; SMN2
SCHEMBL24603669 0.75 LPAR1 (0.41) LPAR1MEN1KMT2ALPAR5TSHR
SCHEMBL24603655 0.73 MAPT (0.47) MEN1KMT2ATSHRSMN1; SMN2TP53
SCHEMBL24604088 0.72 KDM4E (0.37) MEN1KMT2ATP53KDM4E
SCHEMBL24603666 0.69 ALDH1A1 (0.51) MEN1KMT2ASMN1; SMN2TDP1KDM4E
SCHEMBL16506845 0.66 LPAR1 (0.83) LPAR1LPAR5HDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025901-A1 METHOD FOR PRODUCING CYCLIC IMIDE COMPOUND, COMPOSITION, AND COMPOUND FUJIFILM CORPORATION (JP) 2024-01-25 — — US disclosed
US-20220213104-A1 METHOD FOR PRODUCING CYCLIC IMIDE COMPOUND, COMPOSITION, AND COMPOUND FUJIFILM CORPORATION (JP) 2022-07-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025901-A1 METHOD FOR PRODUCING CYCLIC IMIDE COMPOUND, COMPOSITION, AND COMPOUND INF2, NISCH, ITPA LPAR1 2970/4885MEN1 91/4885KMT2A 2582/4885
US-20220213104-A1 METHOD FOR PRODUCING CYCLIC IMIDE COMPOUND, COMPOSITION, AND COMPOUND INF2, NISCH, ITPA LPAR1 2970/4885MEN1 91/4885KMT2A 2582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback